Nektar Therapeutics (NKTR) · Aug 13, 2026 · Earnings

The EPS beat is real—but mostly a share-count illusion

Beat — GAAP EPS $(1.23) vs published consensus near $(2.04)

Nektar beat the EPS bar, but revenue slipped and heavier Phase 3 spending makes the headline improvement less impressive.

The headline EPS result beat the market’s bar, but revenue slightly missed. Nektar posted GAAP loss per share of $1.23 versus published consensus near $2.04, while revenue came in at $10.1 million versus roughly $10.5 million expected.

MetricQ2 2026Q2 2025Change
Revenue$10.1M *(Financial Highlights)*$11.2MDown 9%
R&D expense$39.1M *(Financial Highlights)*$29.9MUp 31%
Operating costs and expenses$52.5M *(Financial Highlights)*$47.4MUp 11%
Net loss$(40.6)M *(Income Statement)*$(41.6)MImproved 2%
GAAP loss per share$(1.23) *(Income Statement)*$(2.95)Improved 58%
Weighted-average shares33.1M *(Income Statement)*14.1MUp 135%
Cash and investments$1.02B *(Balance Sheet)*$245.8MUp sharply

The EPS improvement overstates the underlying operating progress. Net loss improved only modestly, while the weighted-average share count more than doubled, making the per-share loss look dramatically better. At the same time, R&D spending rose $9.2 million as Phase 3 ZENITH activities and manufacturing ramped. *(Financial Highlights; Income Statement)*

The strategic picture strengthened through funding, not earnings power. Cash, short-term investments, and long-term investments totaled approximately $1.02 billion at quarter-end, with management projecting runway into the third quarter of 2028 and initial Phase 3 readouts in mid-2028. *(Balance Sheet; Management Commentary)* The balance sheet also shows capital in excess of par value rising by roughly $901 million, consistent with substantial equity financing; that explains the dilution behind the per-share result. *(Balance Sheet)*

Net read: a narrow earnings beat, tempered by weaker revenue quality and dilution. The filing supports continued execution toward Phase 3, but it does not show commercial momentum: royalty revenue declined, operating losses remained heavy, and development costs are accelerating. Against consensus, the EPS beat is enough for a “Beat” scorecard, but the favorable signal is narrower than the headline suggests.

What to watch next

Initial Phase 3 data readouts expected mid-2028

Original filing on SEC EDGAR

More Nektar Therapeutics news

The EPS beat is real—but mostly a share-count illusion | NKTR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.